Gene · 8019
Papers2,104
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 2,104
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder cancer: a bioinformatics research. | BMC Urol | 2022 | 35879749 | PubTator, text mining | PubMed |
| Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2. | Neurooncol Adv | 2022 | 35855490 | PubTator, text mining | PubMed |
| BET-Independent Murine Leukemia Virus Integration Is Retargeted In Vivo and Selects Distinct Genomic Elements for Lymphomagenesis. | Microbiol Spectr | 2022 | 35852337 | PubTator, text mining | PubMed |
| Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer. | Breast Cancer Res | 2022 | 35850772 | PubTator, text mining | PubMed |
| Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia. | J Exp Clin Cancer Res | 2022 | 35842703 | PubTator, text mining | PubMed |
| Viral E protein neutralizes BET protein-mediated post-entry antagonism of SARS-CoV-2. | Cell Rep | 2022 | 35839775 | PubTator, text mining | PubMed |
| Case report: NUT carcinoma in an elderly woman with unique morphology and immunophenotype highlights a diagnostic pitfall. | Transl Cancer Res | 2022 | 35836519 | PubTator, text mining | PubMed |
| NUT Midline Carcinoma: A Rare Solid Tumour Characterized by Chromosome Rearrangement. | Evid Based Complement Alternat Med | 2022 | 35832518 | PubTator, text mining | PubMed |
| A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. | Pathol Oncol Res | 2022 | 35832114 | PubTator, text mining | PubMed |
| Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery. | Nat Commun | 2022 | 35831314 | PubTator, text mining | PubMed |
| Transcriptional enhancers at 40: evolution of a viral DNA element to nuclear architectural structures. | Trends Genet | 2022 | 35811173 | PubTator, text mining | PubMed |
| Genetic variation associated with condensate dysregulation in disease. | Dev Cell | 2022 | 35809564 | PubTator, text mining | PubMed |
| LncRNAs in breast cancer: a link to future approaches. | Cancer Gene Ther | 2022 | 35788171 | PubTator, text mining | PubMed |
| Inhibition of BET Family Proteins Suppresses African Swine Fever Virus Infection. | Microbiol Spectr | 2022 | 35758684 | PubTator, text mining | PubMed |
| Emerging Proteins in CRPC: Functional Roles and Clinical Implications. | Front Oncol | 2022 | 35756667 | PubTator, text mining | PubMed |
| Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. | Signal Transduct Target Ther | 2022 | 35750683 | PubTator, text mining | PubMed |
| Alternative Mechanisms for DNA Engagement by BET Bromodomain-Containing Proteins. | Biochemistry | 2022 | 35748495 | PubTator, text mining | PubMed |
| Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures. | Pharmaceuticals (Basel) | 2022 | 35745664 | PubTator, text mining | PubMed |
| Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors. | Pharmaceuticals (Basel) | 2022 | 35745584 | PubTator, text mining | PubMed |
| Metabolic and Molecular Mechanisms of Diet and Physical Exercise in the Management of Polycystic Ovarian Syndrome. | Biomedicines | 2022 | 35740328 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8019/papers?page=25